PGEN

Precigen, Inc. operates as a biopharmaceutical company specializing in the development of gene and cell therapies for cancer and infectious diseases. Headquartered in Germantown, Maryland, the company leverages its proprietary UltraCAR-T™ platform technology to engineer next-generation chimeric antigen receptor T-cell therapies designed to improve efficacy and safety profiles. Precigen focuses on advancing therapies targeting AML, ovarian cancer, and other solid tumors through its pipeline of investigational treatments. The company also develops its AdenoVerse™ immunotherapy platform for vaccine applications, including candidates for HPV-associated cancers and infectious disease prevention. Precigen operates through collaborations with strategic partners and maintains research facilities supporting its synthetic biology capabilities. The company's business model centers on advancing wholly-owned programs while selectively partnering on platform applications. In recent developments, Precigen has concentrated resources on advancing its lead CAR-T candidates through clinical trials, with PRGN-3005 for ovarian cancer and PRGN-3006 UltraCAR-T for AML progressing through development stages. The company emerged from a 2020 corporate restructuring that separated its therapeutics business from its legacy bioprocessing operations. Precigen employs approximately 150 people and focuses its capital allocation on clinical-stage assets with near-term commercial potential. The company reports financial results as a clinical-stage biopharmaceutical entity with no current product revenue.